We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Novartis AG | NYSE:NVS | NYSE | Depository Receipt |
| Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.62 | -1.64% | 97.44 | 98.22 | 97.44 | 97.76 | 1,562,845 | 21:20:33 |
From Apr 2019 to Apr 2024
LONDON-- Medical inhaler company Vectura Group PLC (VEC.LN) Wednesday announced a collaboration with Sandoz, a division of Swiss drug giant Novartis AG (NVS), to develop a generic version of an inhaler therapy for asthma and chronic obstructive pulmonary disease.
Vectura will receive an initial payment of $5 million from Sandoz and up to $5 million more depending on targets. It expects its research and development costs to be less than $20 million.
-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan
(END) Dow Jones Newswires
June 28, 2017 12:39 ET (16:39 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Novartis Chart |
1 Month Novartis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
